<DOC>
	<DOCNO>NCT00759785</DOCNO>
	<brief_summary>A study evaluate response growth factor signatures single dose Dalotuzumab patient stage I-IIIa breast cancer .</brief_summary>
	<brief_title>A Study Dalotuzumab ( MK0646 ) Breast Cancer Patients ( 0646-013 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient operable stage IIIIa breast cancer follow subtypes : ( 1 ) ERnegative , PRnegative , HER2negative breast cancer ; ( 2 ) ERpositive tumor meet one follow criterion histologic grade 3 ; histologic grade 2 PRnegative ; histologic grade 2 Ki67 &gt; 10 % . Tumor least 2 cm diameter assess physical radiographic exam Patient female &gt; 18 year age Patient pregnant , breastfeed plan become pregnant study Patient receive prior chemotherapy , biological therapy radiation Patient participate clinical trial last 30 day Patient history drug alcohol abuse last year Patient HIV positive . Patient history Hepatitis B C Patient poorly control diabetes mellitus .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>